ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

Vipul Jairath  ¹     Marijana Protic  ²     Walter Reinisch  ³     Gert De Hertogh  ⁴     Noam Harpaz  ⁵     Rish Pai  ⁶     Zhantao Lin     Rebecca Hozak     Hilde Carlier     Fernando Magro  ^7    
1 Western University, London, Canada
² Eli Lilly and Company, Indianapolis, United States
³ Medical University of Vienna, Wien, Austria
⁴ University Hospital Leuven, Leuven, Belgium
⁵ Icahn School of Medicine at Mount Sinai, New York, United States
⁶ Mayo Clinic, Scottsdale, United States
⁷ Centro Hospitalar São João, Porto, Portugal

Topic
Endoscopy, Histopathology, IBD

Session
IL-23-Blockers in IBD: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)